Difference between revisions of "Plinabulin (NPI-2358)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=488984 NCI Drug Dictionary]: An orally active diketopiperazine derivative wi...") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
||
| Line 9: | Line 9: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Oral | + | [[Category:Oral medications]] |
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 17:43, 25 July 2017
Mechanism of action
From the NCI Drug Dictionary: An orally active diketopiperazine derivative with potential antineoplastic activity. Plinabulin selectively binds to the colchicine-binding site of tubulin, thereby interrupting equilibrium of microtubule dynamics; mitotic spindle assembly is disrupted, resulting in cell cycle arrest at the M phase and blockage of cell division in tumor cells. In addition, this agent induces tubulin depolymerization in vascular endothelial cells, resulting in the disruption of tumor blood vessel architecture and a selective collapse of tumor vasculature.
Preliminary data
Non-small cell lung cancer
- Abstract: Ramon W. Mohanlal, Ken LLoyd, Lan Huang, Lyudmila Bazhenova. Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC. J Clin Oncol 35, 2017 (suppl 7S; abstract 139) link to abstract